• Company
• Samsung Bioepis’ Opuviz recommended for approval in Europe
• by Whang, byung-woo Sep 24, 2024 05:46am

• Company
• Will Wegovy launch in KOR continue the Saxenda syndrome?
• by Moon, sung-ho Sep 24, 2024 05:46am

• Company
• Severe asthma biologic 'Nucala' available in the 'Big 5'
• by Eo, Yun-Ho Sep 24, 2024 05:46am

• Company
• Hugelsets sights on Indonesia with botulinum toxin Letybo
• by 어윤호 Sep 23, 2024 09:40am

• Company
• Why royalties for Yuhan’s Leclaza were reduced $300mil
• by Chon, Seung-Hyun Sep 23, 2024 05:51am

• Company
• Will the high-priced Hemgenix be reimbursed in Korea?
• by Whang, byung-woo Sep 23, 2024 05:50am

• Company
• Will restrictions on oral SMA drug Evrysdi be lifted?
• by Eo, Yun-Ho Sep 23, 2024 05:50am

• Company
• Peter Trang will head Business Operations at Takeda Korea
• by Whang, byung-woo Sep 20, 2024 05:51am

• Company
• Ipsen Korea appoints Yang mi-sun as new CEO
• by Eo, Yun-Ho Sep 20, 2024 05:51am

• Company
• Inventage Lab to codevelop a long-acting injectable with BI
• by Lee, Seok-Jun Sep 20, 2024 05:51am